Global biopharmaceutical company Ipsen has today announced a €25m investment in its Irish manufacturing site in Blanchardstown, Dublin.

Ipsen said the new investment will significantly increase its capacity in Ireland to produce vital medical treatment that helps patients suffering from both niche cancers and rare diseases.

In Dublin for over 30 years, Ipsen said the new investment is part of its continued growth in the Irish market.

Since 2019 Ipsen has expanded its team in Ireland by over 20%, with 165 employees now working at the Blanchardstown site across research and development, manufacturing and commercial operations.

Tim Shanahan, vice president of manufacturing for Ipsen Manufacturing Ireland, said the country is a very important market for the company.

"We have invested €60m in capital projects in Ireland in the last five years and are proud to announce a further €25m to scale up our manufacturing capacity and enable us to produce even more transformative medicine for patients suffering from rare and life-threatening conditions," Mr Shanahan said.

"We are confident that this investment and our continued growth in the Irish market, will enable us to continue innovating and working towards better treatment and care for patients who need it most," he added.